Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FERINJECT vs placebo for thrombocytosis due to iron deficiency in inflammatory bowel disease
2006-003328-12Phase 2Completed
- Sponsor
- CSL Vifor
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in inflammatory bowel disease (IBD) and iron deficiency anemia (IDA) comparing Ferinject with Placebo (2 arms). Primary endpoint: Platelet count reduction at 6 weeks. Started Nov 2006; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
inflammatory bowel disease (IBD)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2006-003328-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003328-12.